Charles A Conrad

This inventor holds 22 USPTO granted patents and 10 published patent applications and 8 EPO patents, primarily in Cancer Therapeutics. Top assignees: The University of Texas System, Dnatrix, Inc., Lumatherm, Inc.. Active years: 1999-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles A Conrad. Retrieved from https://idiyas.com/inventor/charles-a-conrad

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 10)

% Patents Active = 81.8

EPO Patents = 8 (Patent Applications = 6)

Average Co-Inventor Count = 3.7

ph-index = 8

Forward Citations = 211(Granted Patents)

Location History:

Newport Beach, CA (US) (1999)
Houston, TX (US) (2000 - 2019)
(2019)
Spring, TX (US) (2002 - 2021)
Austin, TX (US) (2021 - 2024)

Company Filing History:

16 out of 5,640

The University of Texas System

6. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

Areas of Expertise:

Oncolytic Virus

Cancer Biomarkers

Glycolysis Inhibitors

Therapeutic Genes

Immunomodulation

2-Deoxy-Monosaccharides

Caffeic Acid

Signal Transducer

Skin Disorders

Anticancer Activity

Combination Therapy

DNA Binding Agents

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11925654 - Esters of 2-deoxy-monosaccharides with anti proliferative activity (2024-03-12),

2. 11090344 - Adenovirus and immunomodulator combination therapy (2021-08-17),

3. 11065285 - Biomarkers and combination therapies using oncolytic virus and immunomodulation (2021-07-20),

4. 11026960 - Esters of 2-deoxy-monosaccharides with anti proliferative activity (2021-06-08),

5. 10358439 - DNA binding agents with a minor groove binding tail (2019-07-23),

6. 10238698 - Biomarkers and combination therapies using oncolytic virus and immunomodulation (2019-03-26),

7. 10201554 - Esters of 2-deoxy-monosacharides with anti proliferative activity (2019-02-12),

8. 10080774 - Oncolytic adenovirus armed with therapeutic genes (2018-09-25),

9. 9149489 - Inhibitors of glycolysis useful in the treatment of brain tumors (2015-10-06),

10. 9061055 - Oncolytic adenovirus armed with therapeutic genes (2015-06-23),

11. 9000179 - Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) (2015-04-07),

12. 8927506 - Acetates of 2-deoxy monosaccharides with anticancer activity (2015-01-06),

13. 8779151 - Orally bioavailable caffeic acid related anticancer drugs (2014-07-15),

14. 8637675 - Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS) (2014-01-28),

15. 8450337 - Methods of treating skin disorders with caffeic acid analogs (2013-05-28),

Title: Charles A. Conrad: Innovator in Cancer Therapeutics and Glycolysis Inhibition

Introduction

Charles A. Conrad, based in Houston, Texas, is a distinguished inventor with an impressive portfolio comprising 22 patents. His innovative contributions primarily focus on the fields of cancer treatment and biochemical methods of inhibition, reflecting his dedication to advancing medical science.

Latest Patents

Among his latest patents are groundbreaking developments such as "Esters of 2-deoxy-monosaccharides with anti-proliferative activity." This patent discloses compounds and methods aimed at inhibiting glycolysis, thereby providing potential treatments for cancer and various other diseases. Another notable patent is related to "Adenovirus and immunomodulator combination therapy," which explores enhancements in the effectiveness of adenoviral cancer therapies, showcasing his commitment to improving therapeutic outcomes in oncology.

Career Highlights

Charles has made significant strides in his career, particularly during his tenure with the University of Texas System. His work demonstrates a persistent drive to harness scientific research for practical applications, particularly in the realms of health and medicine. His 22 patents bear testimony to his innovative approach and unwavering dedication to finding solutions to complex medical challenges.

Collaborations

Throughout his career, Charles has collaborated with remarkable individuals, including Timothy Madden and Waldemar Priebe. These partnerships have likely enriched his research pursuits and contributed to the success of his innovative endeavors in the medical field.

Conclusion

Charles A. Conrad stands out as a remarkable inventor whose efforts in patenting significant medical advancements are crucial to enhancing cancer therapies and the understanding of glycolytic pathways. His dedication to innovation continues to inspire future generations of inventors and researchers in the field of medicine.

Profile summary based on public USPTO records.